On Wednesday, September 4, Johns Hopkins Medicine announced the opening of a research center devoted to studying psychedelic substances for mental health conditions. Backed by $17 million in private donations, it is the US’s first center focused on psychedelic substances and the world’s largest.
The Center for Psychedelic and Consciousness Research will study the effects of psychedelic treatments on behavior, brain function, learning and mood, and the brain’s biology and mood. Six faculty neuroscientists, experimental psychologists, and clinicians with expertise in psychedelic science will staff the facility.
“The center’s establishment reflects a new era of research in therapeutics and the mind through studying this unique and remarkable class of pharmacological compounds,” Roland Griffiths, the center’s director and a professor of behavioral biology, said in a statement.
“In addition to studies on new therapeutics, we plan to investigate creativity and well-being in healthy volunteers that we hope will open up new ways to support human thriving.”
Earlier this year, Imperial College launched the world’s first center dedicated to psychedelic research. Like Johns Hopkins, it was backed exclusively by private donors, raising a total sum of $3.5 million from five founding donors.
As expected, the third wave of psychedelics continues to generate significant momentum, as Western culture and society learn more about the utility of psychedelic substances. With psilocybin and MDMA clinics slated to open in 2021, it won’t be long before psychedelics become an integral part of our healthcare system.